Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gary A. Lyons departed as Director at Eledon Pharmaceuticals, Inc..
- Action
- retiring
- Role
- Director
Exact text from the filing
On April 26, 2023, Gary A. Lyons notified the Company that he is retiring from the Board of Directors of the Company at the end of his term and will not be standing for election at the Company’s 2023 annual meeting of stockholders.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Eledon Pharmaceuticals, Inc. entered into Registration Rights Agreement with Institutional and accredited investors valued at Company to file registration statement within 20 days, use best efforts to have it declared effectiv (effective 2023-04-28).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Institutional and accredited investors
- Value
- Company to file registration statement within 20 days, use best efforts to have it declared effectiv
- Effective
- 2023-04-28
Exact text from the filing
In connection with the Private Placement, the Company entered into a registration rights agreement, dated April 28, 2023 (the “Registration Rights Agreement”), with the Purchasers, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 to register for resale the Shares and the shares of Common Stock issuable upon the exercise of the Warrants within 20 calendar days, and (ii) use its reasonable best efforts to have the registration statement declared effective promptly after filing, and in any event no later than 60 days after the date of the Securities Purchase Agreement (or 90 days after the date of the Securities Purchase Agreement if the registration statement is reviewed by the SEC).
View on SEC.gov